Moss, 9 May 2017
Gentian Diagnostics AS announces its results for the first quarter.
The highlights of the quarter include:
- Plasma calprotectin test on track to be launched in the
second half of 2017
- Continued progress in all development projects
- Proof-of-Concept achieved for G-1001 and the Nanosense II
technology
- Successful completion of MNOK 100 equity raise
- Swedish subsidiary Gentian Diagnostics AB opened in March
Please find the report for the first quarter enclosed. The
report will also be made available on www.gentian.no.
For further information, please contact:
Bård Sundrehagen
CEO, Gentian Diagnostics
E-mail: Bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117